Surgery Partners price target lowered to $32 from $35 at Barclays

Barclays lowered the firm’s price target on Surgery Partners to $32 from $35 and keeps an Equal Weight rating on the shares post the Q2 report. While the company’s year-to-date free cash flow appears behind schedule, seasonal increases in earnings and working capital make the full-year target more realistic, the analyst tells investors in a research note.